Our long-term goal is to integrate non-small cell lung cancer patient treatment preferences into clinical treatment planning.

The following specific aims are proposed:

Aim 1: Determine whether individual patients' preferences, characteristics, and treatment experiences affect the definition of treatment success.

Aim 2: Determine how to best predict real-life patients' treatment choices based on patients' preferences of adverse events.

Aim 3: Determine whether physicians are likely to change their oncologic clinical practice after receiving a detailed communication of their patients' preferences of adverse events.

Inclusion Criteria:

• Willing and able to provide consent

• Greater than or equal to 19 years of age

• Diagnosed with stage IV non-small cell lung cancer (NSCLC)

• Able to understand spoken English

• Eligible to undergo chemotherapy for stage IV NSCLC, to include, but not limited to, those who:

  1. have not yet started chemo
  2. are currently undergoing chemo for stage IV NSCLC
  3. have completed first line stage IV NSCLC chemo or progressed to maintenance for stage IV NSCLC within the last 30 days
  4. elect to have chemo elsewhere -- not at one of the study sites
  5. decline chemo

Exclusion Criteria:

• Age <19 years
• Not willing and/or able to provide consent
• Not able to understand spoken English
• Not eligible to undergo chemotherapy for stage IV NSCLC

Newly diagnosed advanced stage non-small cell lung cancer patients with age > 19 years.